Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR

Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly

NCT02493517 ·Status: COMPLETED ·Phase: PHASE3

Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel

NCT00447499 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly

NCT00234572 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects

NCT02807233 ·Status: COMPLETED

Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)

NCT00517491 ·Status: WITHDRAWN ·Phase: PHASE2

Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients

NCT00383708 ·Status: COMPLETED ·Phase: PHASE3

Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma

NCT00690898 ·Status: COMPLETED ·Phase: PHASE3

Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction

NCT00145405 ·Status: COMPLETED ·Phase: PHASE4

Study to Predict Lanreotide-induced Disease Activity Normalization in Acromegaly

NCT04003519 ·Status: WITHDRAWN

Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly

NCT01137682 ·Status: COMPLETED ·Phase: PHASE3

Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly

NCT00627796 ·Status: COMPLETED ·Phase: PHASE4

Quality of Life (QoL) in Subjects With Acromegaly Under Lanreotide Autogel® Treatment.

NCT02396966 ·Status: COMPLETED

Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly

NCT02396953 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Predictive Factors Study

NCT02020499 ·Status: TERMINATED

Lanreotide Levels in Acromegaly

NCT00916916 ·Status: UNKNOWN

Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly

NCT00600886 ·Status: COMPLETED ·Phase: PHASE3

Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients

NCT00128232 ·Status: COMPLETED ·Phase: PHASE3

Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly

NCT00225979 ·Status: COMPLETED ·Phase: PHASE3

Somatuline Predictive Factors in Acromegaly and NET

NCT01840449 ·Status: COMPLETED

Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China

NCT05431803 ·Status: COMPLETED

Acromegaly Combination Treatment Study

NCT01538966 ·Status: TERMINATED ·Phase: NA

Non Interventional Post Marketing Programme in Acromegaly

NCT00747500 ·Status: COMPLETED

Ultrasound Guided Octreotide LAR Injection in Acromegaly

NCT00552071 ·Status: COMPLETED ·Phase: PHASE4

An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly

NCT01995734 ·Status: APPROVED_FOR_MARKETING

One Year Follow-up of Study 2-79-52030-207 (PRIMARYS) in Acromegalic Patients With Macroadenoma

NCT01471405 ·Status: COMPLETED